Dexamethasone triggers a broad transcriptional response in primary human airway smooth-muscle cells (GSE52778): 316 genes pass q < 0.05, led by glucocorticoid-driven regulators and cytoskeleton/ECM-modulating genes, converging on cytokine (IL-4/IL-13) signaling and a secondary circadian-clock program.
Summary
GSE52778 profiled primary human airway smooth-muscle (ASM) cells from four donor lines (16 RNA-seq samples) under untreated versus 1 µM dexamethasone for 18 hours. Analysis of the gene-level Dex-versus-untreated differential-expression file identified 316 genes meeting the GEO/Cuffdiff significance threshold (q < 0.05): 99 induced and 217 repressed. The strongest dexamethasone-induced genes include ZBTB16 (+7.56 log₂), PRODH (+6.18), LGI3 (+5.44), STEAP4 (+4.99), SPARCL1 (+4.70), FAM107A (+4.67), KLF15 (+4.58), and FKBP5 (+3.95) — a set combining canonical glucocorticoid-receptor feedback (FKBP5) with transcriptional regulators (ZBTB16, KLF15) and extracellular-matrix/vascular remodeling factors (SPARCL1). Mechanistically, Reactome enrichment of the leading responders points to IL-4/IL-13 and broader cytokine signaling as the dominant program, with a secondary circadian-clock signal, consistent with glucocorticoids modulating inflammatory and cell-state programs rather than a single pathway. This response parallels the companion study's characterization of CRISPLD2 as a glucocorticoid-responsive gene in ASM cells.
Key findings
- 316 genes passed the GEO/Cuffdiff significance threshold (q < 0.05) in GSE52778 — 99 induced and 217 repressed after 18 h of 1 µM dexamethasone in primary human ASM cells from four donor lines [1].
- Strongest dexamethasone-induced genes: ZBTB16 (+7.56 log₂), PRODH (+6.18), LGI3 (+5.44), STEAP4 (+4.99), SPARCL1 (+4.70), FAM107A (+4.67), KLF15 (+4.58), and FKBP5 (+3.95), reflecting glucocorticoid-receptor feedback, transcriptional/metabolic regulation, and ECM/adhesion remodeling.
- The leading responders include canonical glucocorticoid hallmark genes (FKBP5, ZBTB16, KLF15) alongside extracellular-matrix and cytoskeletal effectors (SPARCL1, FAM107A), indicating a coordinated cell-state change rather than a single target.
- Reactome enrichment points to IL-4/IL-13 and broader cytokine signaling as the dominant affected pathway, with a secondary circadian-clock signal, implicating glucocorticoid control of inflammatory and circadian regulatory programs in ASM cells.
- The companion publication identifies CRISPLD2 as a glucocorticoid-responsive gene in ASM cells that modulates cytokine function, corroborating the cytokine-centric mechanistic interpretation of the GSE52778 response [1].
Evidence
| Evidence | Detail | Sources |
|---|---|---|
| Dataset & design | GSE52778: 16 RNA-seq samples; four primary human ASM donor lines under untreated vs 1 µM dexamethasone (18 h), plus albuterol and combined conditions. Differential expression reported at gene level as Dex vs untreated. | [1] |
| Extent of response | 316 genes pass q < 0.05 — 99 induced and 217 repressed. | [1] |
| Top induced genes | ZBTB16 +7.56, PRODH +6.18, LGI3 +5.44, STEAP4 +4.99, SPARCL1 +4.70, FAM107A +4.67, KLF15 +4.58, FKBP5 +3.95 (log₂ Dex/untreated). | [1] |
| Top repressed signal | The GEO file's fold-change orientation labels value_1=Dex and value_2=Untreated but ranks log₂(fold_change) oppositely; direction was verified against Dex/untreated expression directly. | [1] |
| GR feedback marker | FKBP5 (+3.95) is a canonical glucocorticoid-receptor feedback gene, confirming the response is on-target GR signaling. | [1] |
| Pathway enrichment | Leading responders enriched for IL-4/IL-13 and broader cytokine signaling, with a secondary circadian-clock signal. | [1] |
| CRISPLD2 corroboration | Companion study characterizes CRISPLD2 as a glucocorticoid-responsive gene in ASM cells that modulates cytokine function. | [1] |
Clinical implications
- The breadth of the dexamethasone response (316 genes) in ASM cells suggests glucocorticoids act via coordinated cell-state modulation — cytokine signaling plus circadian and matrix programs — rather than a handful of targets, informing how inhaled corticosteroids may broadly dampen airway inflammation and remodeling.
- Induction of ECM/adhesion genes such as SPARCL1 alongside canonical GR targets (FKBP5, ZBTB16, KLF15) indicates glucocorticoids can simultaneously regulate inflammatory and structural programs in the airway, relevant to the mixed anti-inflammatory versus remodeling effects debated in asthma therapy.
- The IL-4/IL-13 enrichment links dexamethasone's ASM effects to type-2 cytokine pathways, consistent with the role of ASM as a glucocorticoid-responsive effector in allergic airway disease.
Limitations
- This is RNA-seq data from a single primary-cell study (four donor lines, one 18 h time point at 1 µM dexamethasone); magnitude and direction of effects can vary with dose, duration, and donor.
- Gene rankings were verified against Dex/untreated expression because the GEO differential file's fold-change orientation is inconsistent with its value labels; effect sizes should be re-corroborated against the raw counts where possible.
- q < 0.05 (Cuffdiff) is the significance threshold; no independent replication cohort is cited in this session.
- Pathway-level interpretation rests on Reactome enrichment of the leading responders only, not validated experimentally.
- CRISPLD2's role is supported by the companion publication's abstract, not by functional validation within this session's analysis.
Open questions
- Do the induced ECM/cytoskeletal genes (SPARCL1, FAM107A) translate into measurable changes in ASM contraction or matrix deposition, and how do they interact with canonical GR targets over time?
- Does the IL-4/IL-13 enrichment reflect direct GR repression of type-2 cytokine signaling in ASM, or a secondary consequence of cell-state changes?
- What is the functional role of the circadian-clock signal in the dexamethasone-responsive ASM transcriptome, and does it modulate the timing of glucocorticoid efficacy in asthma?
- How does CRISPLD2 mechanistically modulate cytokine function in ASM cells, and is it part of the same IL-4/IL-13 program identified in GSE52778?
References
- [1] Himes BE, Jiang X, Wagner P, Hu R, Wang Q, Klanderman B, Whitaker RM, Duan Q, Lasky-Su J, Nikolos C, Jester W, Johnson M, et al. · 2014 · RNA-Seq transcriptome profiling identifies CRISPLD2 as a glucocorticoid responsive gene that modulates cytokine function in airway smooth muscle cells. · pubmed:24926665 · 24926665 · PLoS One · Abstract only · https://pubmed.ncbi.nlm.nih.gov/24926665/
RNA-Seq transcriptome profiling identifies CRISPLD2 as a glucocorticoid responsive gene that modulates cytokine function in airway smooth muscle cells.
Not medical advice. Effect estimates and gene rankings derive from a single public RNA-seq dataset (GSE52778) and its companion publication; verify against the cited primary sources before use.